Aeglea BioTherapeutics COO Leslie Sloan departs Jan 5, 2023; receives severance package

Spyre Therapeutics, Inc.

COO Leslie Sloan departed Jan 5, 2023; departure not tied to legal or compliance matters.
Severance includes $435,000 salary continuation (12 months), $174,000 lump-sum bonus, and 12 months COBRA coverage.
Unvested stock options accelerate vesting for an additional 12 months beyond separation date.
No successor COO has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leslie Sloan

Chief Operating Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-01-05
Filed: January 6, 2023, 6:59 PM ET

Effective January 5, 2023 (the “Separation Date”), Leslie Sloan will no longer serve as Chief Operating Officer of Aeglea BioTherapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leslie Sloan departed as Chief Operating Officer at Spyre Therapeutics, Inc..

Action: will no longer serve as
Role: Chief Operating Officer

Exact text from the filing

Effective January 5, 2023 (the “Separation Date”), Leslie Sloan will no longer serve as Chief Operating Officer of Aeglea BioTherapeutics, Inc. (the “Company”).

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-002979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.